Literature DB >> 9566585

An in vivo microdialysis study of striatal 6-[18F]fluoro-L-m-tyrosine metabolism.

S Jordan1, K S Bankiewicz, J L Eberling, H F VanBrocklin, J P O'Neil, W J Jagust.   

Abstract

In vivo brain microdialysis was used to monitor 6-[18F]fluoro-L-m-tyrosine (FMT) uptake and metabolism in the striatum of conscious freely moving rats for 3 hours after FMT injection (25 mg/kg, i.v.). Microdialysate collected 20 to 120 min post-dose, contained FMT at a concentration (0.2 to 0.3 nM) approximately ten-fold below that of its metabolite [18F]fluoro-3-hydroxyphenylacetic acid (FPAC; 3.2 to 3.3 nM). D-amphetamine (2.5 mg/kg, i.p.) injected 120 min after significantly increased microdialysate FPAC (3.27 +/- 0.31 nM to 4.51 +/- 0.45 nM) in control but not reserpinized rats. Taken together these data demonstrate FMT is heavily metabolized following its entry into the striatum yielding FPAC which appears to be stored, at least in part, in reserpine sensitive cytoplasmic vesicles. Presynaptic retention of FPAC may contribute to the preferential accumulation of FMT positron emission tomography (PET) signaling in dopaminergic brain areas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9566585     DOI: 10.1023/a:1022478417383

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  16 in total

1.  4-[18F]fluoro-L-m-tyrosine: an L-3,4-dihydroxyphenylalanine analog for probing presynaptic dopaminergic function with positron emission tomography.

Authors:  W P Melega; M M Perlmutter; A Luxen; C H Nissenson; S T Grafton; S C Huang; M E Phelps; J R Barrio
Journal:  J Neurochem       Date:  1989-07       Impact factor: 5.372

2.  Radiofluorinated L-m-tyrosines: new in-vivo probes for central dopamine biochemistry.

Authors:  J R Barrio; S C Huang; D C Yu; W P Melega; J Quintana; S R Cherry; A Jacobson; M Namavari; N Satyamurthy; M E Phelps
Journal:  J Cereb Blood Flow Metab       Date:  1996-07       Impact factor: 6.200

3.  Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model.

Authors:  J F Fischer; A K Cho
Journal:  J Pharmacol Exp Ther       Date:  1979-02       Impact factor: 4.030

4.  Role of vesicular dopamine in the in vivo stimulation of striatal dopamine transmission by amphetamine: evidence from microdialysis and Fos immunohistochemistry.

Authors:  C Cadoni; A Pinna; G Russi; S Consolo; G Di Chiara
Journal:  Neuroscience       Date:  1995-04       Impact factor: 3.590

Review 5.  The tyramine binding site in the central nervous system: an overview.

Authors:  A Vaccari
Journal:  Neurochem Res       Date:  1993-08       Impact factor: 3.996

6.  Ammonia-induced release of neurotransmitters from rat brain synaptosomes: differences between the effects on amines and amino acids.

Authors:  M Erecińska; A Pastuszko; D F Wilson; D Nelson
Journal:  J Neurochem       Date:  1987-10       Impact factor: 5.372

7.  Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile.

Authors:  A M Gonzalez; D Walther; A Pazos; G R Uhl
Journal:  Brain Res Mol Brain Res       Date:  1994-03

8.  Positron emission tomography with 4-[18F]fluoro-L-m-tyrosine in MPTP-induced hemiparkinsonian monkeys.

Authors:  N Hayase; K Tomiyoshi; K Watanabe; S Horikoshi; T Shibasaki; C Ohye
Journal:  Ann Nucl Med       Date:  1995-08       Impact factor: 2.668

9.  Biochemistry of somatodendritic dopamine release in substantia nigra: an in vivo comparison with striatal dopamine release.

Authors:  M J Heeringa; E D Abercrombie
Journal:  J Neurochem       Date:  1995-07       Impact factor: 5.372

10.  Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters.

Authors:  S Schuldiner; S Steiner-Mordoch; R Yelin; S C Wall; G Rudnick
Journal:  Mol Pharmacol       Date:  1993-12       Impact factor: 4.436

View more
  3 in total

1.  A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys.

Authors:  John R Forsayeth; Jamie L Eberling; Laura M Sanftner; Zhu Zhen; Philip Pivirotto; John Bringas; Janet Cunningham; Krystof S Bankiewicz
Journal:  Mol Ther       Date:  2006-06-16       Impact factor: 11.454

2.  PET imaging in rats to discern temporal onset differences between 6-hydroxydopamine and tau gene vector neurodegeneration models.

Authors:  Ronald L Klein; Robert D Dayton; Tracee L Terry; Chris Vascoe; John J Sunderland; Kerrie H Tainter
Journal:  Brain Res       Date:  2009-02-10       Impact factor: 3.252

3.  Dnmt3a2/Dnmt3L Overexpression in the Dopaminergic System of Mice Increases Exercise Behavior through Signaling Changes in the Hypothalamus.

Authors:  Di Cui; Andrea Mesaros; Gregor Burdeos; Ingo Voigt; Patrick Giavalisco; Yvonne Hinze; Martin Purrio; Bernd Neumaier; Alexander Drzezga; Yayoi Obata; Heike Endepols; Xiangru Xu
Journal:  Int J Mol Sci       Date:  2020-08-31       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.